Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have
Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have been encouraging, according to the company. Code 7228, a proprietary coated iron oxide compound, is being groomed for cardiovascular applications.
New Study Assesses Benefits of High-Resolution Photon-Counting for Computed Tomography Angiography
October 10th 2024Researchers found that ultra-high resolution photon-counting significantly enhanced visualization of small vessels and facilitated improved reduction of blooming artifacts for head and neck computed tomography angiography (CTA) scans.
Multicenter Study Identifies Key Factors Associated with Mammogram-Occult Ipsilateral Breast Cancer
October 9th 2024A symptomatic first breast cancer diagnosis, prevailing breast density at a second breast cancer diagnosis and trabecular thickening on surveillance mammography were linked to mammogram-occult ipsilateral breast cancer, according to new research.